Therapeutics Company Announces Positive Data For Solid Tumor Cancer
Alligator Bioscience and Aptevo Therapeutics Report Positive Interim Data in Phase 1 Study of ALG.APV-527 for Solid Tumor Cancers.
In a promising development for cancer research, Alligator Bioscience (Alligator) and Aptevo Therapeutics (Aptevo) have announced positive interim data from the dose escalation phase of their ALG.APV-527 Phase 1 study. The study focuses on patients with solid tumor cancers that express the tumor antigen 5T4. $Aptevo Therapeutics(APVO.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
